Is the Rally Ready to Begin for BioMarin Pharmaceutical?

BMRN stock is consolidating on light volume prior to earnings.  The company is projected to report earnings and revenue that are lower on a year-over-year basis. With a potential upside of over 46%, that could make BioMarin an attractive buying option.

from Entrepreneur https://ift.tt/3aJw1HV
https://ift.tt/3t4l7Tc